Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Warby ParkerWRBY 71 12-1 Month Momentum % is 0.15% as of Aug. 20, 2026. GuruFocus rates WRBY with a GF Score™ of 71/100 and a GF Value™ of $21.57 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 824 Medical Devices & Instruments companies, Warby Parker ranks better than 73.06% on this metric.
12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-08-20), Warby Parker's 12-1 Month Momentum % is 0.15%.
The industry rank for Warby Parker's 12-1 Month Momentum % or its related term are showing as below:
WRBY's 12-1 Month Momentum % is ranked better than 73.06% of 824
companies
in the Medical Devices & Instruments industry
Industry Median: -19.085
vs WRBY: 0.15
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Warby Parker 12-1 Month Momentum % Related Terms
WRBY vs XRAY, LMAT, PLSE: 12-1 Month Momentum % Comparison
For the Medical Instruments & Supplies subindustry, Warby Parker's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Warby Parker 12-1 Month Momentum % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Warby Parker's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Warby Parker's 12-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Warby Parker (WRBY) has a 12-1 Month Momentum % of 0.15% as of Aug. 20, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Warby Parker and its competitors. According to the industry distribution chart, Warby Parker ranks #222 out of 824 companies in the Medical Devices & Instruments industry, placing it in the top 26.9%.
Is Warby Parker's 12-1 Month Momentum % too high?
Warby Parker's current 12-1 Month Momentum % is 0.15%. Based on the distribution chart, Warby Parker ranks #222 out of 824 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Warby Parker has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Warby Parker's 12-1 Month Momentum % compare to XRAY and LMAT?
According to the Medical Devices & Instruments industry distribution chart, Warby Parker ranks #222 out of 824 companies for 12-1 Month Momentum %. This puts Warby Parker in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Medical Devices & Instruments company?
A good 12-1 Month Momentum % depends on the Medical Devices & Instruments industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Warby Parker and its competitors. Warby Parker's current 12-1 Month Momentum % is 0.15%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Warby Parker stock overvalued right now?
Based on GuruFocus' analysis, Warby Parker (WRBY) is currently considered Significantly Overvalued. The stock's GF Value™ is $21.57, compared to a current price of $28.50 — trading 32.1% above its estimated fair value. The current 12-1 Month Momentum % is 0.15%. Warby Parker's overall GF Score™ is 71/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For Warby Parker (WRBY), the current 12-1 Month Momentum % is 0.15% as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Warby Parker (WRBY) Overvalued in 2026?
Based on GuruFocus' analysis, Warby Parker stock appears to be overvalued.
The current stock price of $28.50 is trading 32.1% above its estimated GF Value™ of $21.57.
GuruFocus considers Warby Parker to be Significantly Overvalued.
Key valuation signals for WRBY:
12-1 Month Momentum %: 0.15%
GF Value™: $21.57 vs. price of $28.50 (32.1% above fair value)
No single metric tells the full story. See the WRBY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Warby Parker Inc is a mission-driven, lifestyle brand that operates at the intersection of design, technology, healthcare, and social enterprise. The Company provides holistic vision care by offering eyewear, contacts, and eye care directly to consumers through its integrated, omnichannel platform. The company predominantly derives revenue from the sales of eyewear products, optical services, and accessories. The firm sells products and services through its stores, website, and mobile apps. Revenue generated from eyewear products includes the sales of prescription and non-prescription optical glasses and sunglasses, contact lenses, eyewear accessories, and expedited shipping charges.
71GF Score
Get the complete analysis for WRBY
12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WRBY has been successfully added to your 
